JF
NRIX icon

Jump Financial’s Nurix Therapeutics NRIX Stock Holding History

Jump Financial’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.14M Buy
170,788
+81,270
+91% +$1.38M 0.03% 595
2026
Q1 		$1.39M Buy
89,518
+9,481
+12% +$157K 0.02% 797
2025
Q4 		$1.52M Buy
+80,037
New +$1.15M 0.02% 804
2025
Q2 		– Sell
-76,060
Closed -$904K – 2040
2025
Q1 		$904K Buy
76,060
+1,441
+2% +$24.1K 0.01% 867
2024
Q4 		$1.41M Buy
+74,619
New +$1.71M 0.03% 637
2024
Q1 		– Sell
-15,332
Closed -$158K – 2166
2023
Q4 		$158K Buy
+15,332
New +$105K 0.01% 1609
2023
Q2 		– Sell
-12,100
Closed -$107K – 2047
2023
Q1 		$107K Sell
12,100
-13,173
-52% -$137K ﹤0.01% 1431
2022
Q4 		$277K Sell
25,273
-18,527
-42% -$223K 0.01% 1093
2022
Q3 		$571K Buy
43,800
+5,800
+15% +$91.8K 0.02% 838
2022
Q2 		$481K Buy
38,000
+5,837
+18% +$66.2K 0.02% 870
2022
Q1 		$451K Buy
+32,163
New +$571K 0.02% 862

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jump Financial's NRIX Position: Q2 2026 in Review

Jump Financial increased its Nurix Therapeutics (NRIX) stake by 91% in Q2 2026, buying an estimated $1.38M and bringing the position to 170,788 shares worth $4.14M. The position accounts for 0.03% of the portfolio, ranked #595.

Jump Financial first reported a position in NRIX in Q1 2022 and has held it in 11 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Jump Financial held 170,788 shares of Nurix Therapeutics worth $4.14M as of Q2 2026.
  • Jump Financial bought 81,270 Nurix Therapeutics shares in Q2 2026, an estimated $1.38M.
  • Nurix Therapeutics made up 0.03% of Jump Financial's portfolio in Q2 2026, its #595 holding.
  • Jump Financial first reported a position in Nurix Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.